MarginsXMarginsX
Home › Markets › Health Care › NNVC

NanoViricides Inc. (NNVC)

NNVC trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.24
+0.81% on the day
Market cap
$31.7M
Nano cap
Revenue · 2026
$0
Prior year not contiguous
Net income · 2026
-$8.2M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1379006/000110465926111390/0001104659-26-111390-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerNNVC on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001379006
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2026

LineValue
Revenue$0
Net income-$8.2M
Operating income-$8.3M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$2.8M
Total assets$9.9M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
4.4 months
$2.8M cash at June 30, 2026
Share count, 1 year
+46.4%
2025-09-27 to 2026-09-28 · +117.3% over 3 years
Going-concern doubt
Yes
10-K filed September 28, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As a result, substantial doubt exists about the Company's ability to continue as a going concern."
10-K 2026-09-28
Cash and burn$2.8M cash; operating cash flow -$1.9M a quarter.Report 2026-06-30
Shares outstanding25,525,000 (2026-09-28); 17,431,000 a year earlier; 11,746,000 three years earlier.Cover page 2026-09-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months4 S-3/F-3 shelf filings; 5 424B5 takedowns, 5 at the marketLatest 2026-10-21
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEisnerAmper LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-09-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q4 2026
2026-06-30
$0-$2.2M-$2.1M$2.8MNo debt tags$010-K 2026-09-28
Q3 2026
2026-03-31
$0-$2.0M-$1.9M$3.2MNo debt tags$010-Q 2026-05-15
Q2 2026
2025-12-31
$0-$2.2M-$2.0M$5.2MNo debt tags$010-Q 2026-02-17
Q1 2026
2025-09-30
$0-$1.8M-$1.6M$1.1MNo debt tags$010-Q 2025-11-14
Q4 2025
2025-06-30
$0-$2.1M-$1.7M$1.6MNo debt tags$010-K 2025-09-29
Q3 2025
2025-03-31
$0-$2.2M-$2.0M$2.5MNo debt tags$010-Q 2025-05-15
Q2 2025
2024-12-31
$0-$2.0M-$2.2M$4.0MNo debt tags$010-Q 2025-02-14
Q1 2025
2024-09-30
$0-$3.1M-$2.6M$3.9MNo debt tags$010-Q 2024-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-10-21
Latest annual report10-K2026-09-28
Latest quarterly / interim10-Q2026-05-15
Latest current report
FORM 8-K
8-K2026-09-29
Latest proxyDEF 14A2026-10-08

Source: SEC EDGAR submissions feed, 556 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.8%
1 month-6.8%
3 months-9.6%
Year to date+8.8%
1 year-8.9%
From 52-week high-33.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NSRXNasus Pharma Ltd.$2.66-7.32%$31.2M
NXTCNextCure Inc.$6.68+4.38%$30.6M
PMNProMIS Neurosciences Inc. Common Shares (ON)$3.31+0.61%$29.8M
RNTXRein Therapeutics Inc.$0.4000-27.55%$34.5M
SCYXSCYNEXIS Inc.$2.91-9.35%$29.0M
BCTXBriaCell Therapeutics Corp. Common Shares$3.30-2.65%$28.8M
OSTXOS Therapies Incorporated$0.6807-8.63%$35.4M
TELOTelomir Pharmaceuticals Inc.$0.4810-1.96%$35.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier